



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Rafivirumab

Cat. No.:	HY-P99811
CAS No.:	944548-37-2
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails ^{[1][2][3]} .								
In Vitro	Rafivirumab shows neutralization effect against series of RABV isolates ^[2] . Rafivirumab binds to antigenic site I of the RABV glycoprotein ^[3] . Rafivirumab fully neutralizes the wild type ERA ₄₃₉ and N336D R346K with EC ₅₀ ranging between 3 and 5 µg/mL ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Rafivirumab (3-12 µg/kg,i.m.) together with CR4098 increases survival in syrian hamsters infected with bat rabies viruses ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Syrian hamsters infected with bat rabies viruses^[2].</td> </tr> <tr> <td>Dosage:</td> <td>6, 12, 16, 18 or 24 µg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio)</td> </tr> <tr> <td>Administration:</td> <td>i.m.</td> </tr> <tr> <td>Result:</td> <td>Increased survival rate.</td> </tr> </table>	Animal Model:	Syrian hamsters infected with bat rabies viruses ^[2] .	Dosage:	6, 12, 16, 18 or 24 µg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio)	Administration:	i.m.	Result:	Increased survival rate.
Animal Model:	Syrian hamsters infected with bat rabies viruses ^[2] .								
Dosage:	6, 12, 16, 18 or 24 µg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio)								
Administration:	i.m.								
Result:	Increased survival rate.								

REFERENCES

- [1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. *Eur J Immunol.* 2005 Jul;35(7):2131-45.
- [2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. *Trop Med Infect Dis.* 2017 Sep 20;2(3):48.
- [3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. *Sci Rep.* 2022 Jun 7;12(1):9403.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA